MEDiC Life Sciences is a biotechnology company that is focused on the systematic discovery of biomarkers, synthetic lethality, resistant mutations, and novel drug targets for cancer using its proprietary CRISPR functional genomics platform in 3D tumor models. The company combines the power of CRISPR functional genomics with the accuracy/translatability of patient tumor-like cancer models to identify pathways for cancer drug development. With its platform, MEDiC generates and cultures millions of CRISPR tumor variants in the presence of human T cells designed to attack the tumor variants. This unique co-culture system fully integrated with CRISPR enables the company to systematically identify both tumor-intrinsic drug targets and immuno-oncological drug targets. MEDiC can also identify biomarkers, resistance mutations, and synthetic lethality genes.